Clonal Hematopoiesis of Indeterminate Potential Linked to Increased Risk of Heart Failure: JAMA
Written By : Medha Baranwal
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2026-01-07 03:45 GMT | Update On 2026-01-07 03:45 GMT
Advertisement
USA: Researchers have found in a new cohort study that clonal hematopoiesis of indeterminate potential (CHIP), particularly non-DNMT3A CHIP, was linked to a higher incidence of heart failure (HF). Other CHIP-related comorbidities accounted for only a small part of this relationship, suggesting CHIP itself may be a direct HF risk factor and a possible therapeutic target.
The study, published in JAMA Cardiology
CHIP refers to the age-associated expansion of blood cell clones that acquire preleukemic mutations. While previous studies have connected CHIP to various cardiometabolic disorders, its role in heart failure development—particularly for specific genetic variants—had remained uncertain.
To address this, researchers conducted a large-scale, prospective cohort analysis using data from 417,616 participants in the UK Biobank. None of the participants had heart failure, hematologic cancers, or major CHIP-associated conditions such as coronary artery disease (CAD), atrial fibrillation (AF), type 2 diabetes (T2D), or chronic kidney disease (CKD) at baseline. Whole-exome sequencing (WES) data were analyzed between April and October 2025, and participants were followed for a median duration of 11.1 years.
The primary goal was to determine whether CHIP, or specific CHIP driver genes, were associated with new cases of heart failure. Using Cox regression models adjusted for demographic and cardiovascular risk factors, the researchers assessed both overall CHIP presence and gene-specific variants, including DNMT3A, TET2, ASXL1, JAK2, spliceosome genes, and DNA damage repair genes.
The key findings were as follows:
- During the follow-up period, 7183 participants (1.7%) developed new-onset heart failure.
- The presence of clonal hematopoiesis of indeterminate potential (CHIP) was linked to a 27% higher risk of heart failure (adjusted hazard ratio [aHR] 1.27).
- The association was mainly driven by non-DNMT3A CHIP subtypes, which showed a 52% increased risk of heart failure (aHR 1.52).
- DNMT3A CHIP showed only a modest link with heart failure (aHR 1.15).
- Among the non-DNMT3A variants, the strongest associations were observed for TET2, ASXL1, JAK2, and spliceosome gene mutations.
- CHIP-related comorbidities such as coronary artery disease, atrial fibrillation, type 2 diabetes, and chronic kidney disease collectively accounted for only 28.2% of the association between non-DNMT3A CHIP and heart failure.
- The findings indicate that while CHIP may influence heart failure risk partly through these comorbidities, most of the effect appears to be independent of them.
The authors concluded that CHIP, especially non-DNMT3A subtypes, represents an independent risk factor for the development of heart failure. These insights highlight the potential of CHIP as both a biomarker and a therapeutic target for HF prevention and management.
They further emphasized the need for future research to uncover the gene-specific pathways through which CHIP drives cardiac dysfunction, which could eventually pave the way for targeted interventions aimed at mitigating heart failure risk in individuals with CHIP.
Reference:
Flynn S, Schuermans A, Uddin MM, et al. Clonal Hematopoiesis and Incident Heart Failure. JAMA Cardiol. Published online November 09, 2025. doi:10.1001/jamacardio.2025.4603
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.